CXCL12 and colorectal cancer: The inhibition of CXCL12 or its receptor CXCR4 resulted in increased T-cell infiltration and rendered tumors vulnerable towards checkpoint inhibition therapy in mouse models for pancreatic and colorectal cancer [148,149].